[http://www.lmsoft.com/] CNS REPORT, last update 2012 Scientists elucidating the biochemistry behind depression, anxiety or pain are facing challenges incomparable to other disease areas. First of all, there is no genetic based animal model, no surrogate animal markers and only a limited understanding of biochemistry in animal tests. Secondly, the pacebo effect is unusually high and causes high failure rates in clinical trials. To complicate things further, scientists are confronted with ethical arguments. In the future foreseen by the American President´s Council on Bioethics doctors could give medication 'liberally to soldiers on the eve of combat, to emergency workers en route to a disaster site, or even to individuals requesting prophylaxis against the shame or guilt they might incur from future misdeeds'. They claim an enormous potential for misuse. All these impediments are counterbalanced by the enormous medical need and the resulting market potential. The CNS REPORT give a snapshot of the state of the art. The report describes: · Areas of the brain which are involved in processing and integrating signals mediating emotions and pain · Novel therapeutic approches · Presents a survey of more than 90 marketed and novel therapeutics CNS REPORT is unique in presenting the scientific background behind molecular targets and therapeutics addressing these targets. Thereby, the report strongly supports and facilitates the evaluation of molecular targets and novel therapeutics. The report can be purchased as a PDF file for € 200,- plus VATor as a hard copy version for € 250,- plus VAT. Teaser CNS REPORT
TECHNOLOGY CONSULTING Dr. Roswitha Gropp
[./homepag.html]
[./backgroundpag.html]
[./reportspag.html]
[./cnspag.html]
[./metabolicspag.html]
[./contactpag.html]
[./my_viewpag.html]
[./my_viewpag.html]
Home Background Reports CANCER CNS METABOLICS CANCER STEM CELLS My View No Magic Bullets Contact